Deals and Financings
Cytovant Sciences, a China cell therapy startup, announced a $1 billion partnership with Germany's Medigene (MDGEF) to develop four of Medigene's T cell immunotherapy products in China (see story). Cytovant paid $10 million upfront for the products, and agreed to make up to $1 billion plus in milestone payments. Cytovant, headquartered in Hong Kong, is one of the "vant" companies formed by US-based Roivant around a specific purpose. Last year, Roivant formed Sinovant to develop 11 drug candidates in China.
Beijing Miao Jia Medical Information Technology announced a $74.4 million C